1. Introduction {#sec1-jcm-08-00587}
===============

Tacrolimus (Tac) is recommended by The Kidney Disease: Improving Global Outcomes (KDIGO) guideline as the immunosuppressant of choice after renal transplantation (RTx) \[[@B1-jcm-08-00587]\]. Although it is very effective in terms of preventing organ rejection, its highly inter-individual variable metabolism rate can be a challenging factor for physicians as many factors can impact on Tac metabolism \[[@B2-jcm-08-00587]\]. Different approaches have largely failed to predict the dosing and Tac clearance or could not show the advantages pertaining to safety or outcomes \[[@B3-jcm-08-00587],[@B4-jcm-08-00587],[@B5-jcm-08-00587]\]. Even though genetic polymorphisms have been shown to significantly influence Tac metabolism, genetic testing strategies did not improve clinical outcomes \[[@B6-jcm-08-00587],[@B7-jcm-08-00587]\], and require effort in terms of cost and the interpretation of results and therefore have not found their way into clinical practice yet. Thus, therapeutic drug monitoring is essential for directing the therapy.

We recently proposed a classification of patients receiving Tac into two major metabolism groups. Our stratification is based on the calculation of the C/D ratio (expressed as the trough level concentration normalized by the dose). A C/D ratio \<1.05 ng/mL × 1/mg identifies fast metabolizers, whereas a C/D ratio ≥1.05 ng/mL × 1/mg indicates a slow metabolism \[[@B8-jcm-08-00587]\]. Alternative definitions of the metabolic state category, such as dose requirements \[[@B9-jcm-08-00587]\], clearance rate, or calculation of the D/C ratio, exist \[[@B10-jcm-08-00587],[@B11-jcm-08-00587]\]. Interestingly, fast Tac metabolizers have been found as being more prone to developing BK viremia \[[@B12-jcm-08-00587]\], calcineurin-inhibitor toxicity \[[@B8-jcm-08-00587],[@B9-jcm-08-00587]\], and acute rejections \[[@B10-jcm-08-00587],[@B13-jcm-08-00587],[@B14-jcm-08-00587]\] after RTx. In congruence, kidney function (three to 24 months after RTx and 36 months after liver transplantation, respectively) was lower in fast than in slow metabolizers \[[@B8-jcm-08-00587],[@B9-jcm-08-00587],[@B15-jcm-08-00587],[@B16-jcm-08-00587]\]. Based on these findings, suggesting an influence of fast Tac metabolism on adverse events and inferior renal function after renal transplantation, the aim of this study was to analyze whether Tac metabolism type might even impact on definite outcomes such as patient and graft survival and to identify whether fast Tac metabolism constitutes an independent risk factor that physicians should consider besides already known determinants of kidney transplant patients' long-term outcome. Hypothesizing that Tac metabolism-dependent effects on mortality might become discernable in the long-term, the present study was performed in a patient cohort with a complete five-year follow-up.

2. Methods {#sec2-jcm-08-00587}
==========

2.1. Patients {#sec2dot1-jcm-08-00587}
-------------

Prior to analysis, all patient data was anonymized and de-identified. The local ethics committee (Ethik Kommission der Ärztekammer Westfalen-Lippe und der Medizinischen Fakultät der Westfälischen Wilhelms-Universität, No. 2014-381-f-N) approved the study. The methods used in this study were carried out in accordance with the current transplantation guidelines and the Declarations of Istanbul and Helsinki. Written informed consent with regard to recording their clinical data was given by all participants at the time of transplantation.

We retrospectively analyzed all patients who underwent RTx between January 2007 and December 2012 at the University Hospital Münster and were initially treated with an immunosuppressive regimen containing Tac (Prograf^®^), mycophenolate mofetil, prednisolone, and induction therapy. Oral CMV-prophylaxis with valganciclovir was administered for 100 days for D+/R+, D−/R+ and D+/R− recipients, and none if both the donor and the recipient were negative for CMV. Recipients aged \< 18 years, with combined transplants, and for whom the three month C/D ratio could not be adequately calculated (due to Tac-free immunosuppressive regimen, missing data, or simultaneous higher dosage of prednisolone (≥20 mg/day, which is known to induce CYP3A activity)) were excluded. The Tac target trough level was 6--10 ng/mL. Recipient and donor data was collected from the patient files. The following parameters were examined: Patient and donor demographics, recipient body mass index (BMI), recipient history of hypertension or diabetes mellitus, cause of end-stage renal disease (ESRD), number of prior kidney transplants, time on dialysis, donor type of transplantation, degree of human leukocyte antigen (HLA)-mismatching, current panel-reactive antibodies (PRA), cold and warm ischemia time and incidence of new-onset diabetes after transplantation (NODAT) and cytomegalovirus (CMV) DNAaemia (a number of \>600 copies/mL was considered as relevant corresponding to the threshold value given by the manufacturer (TaqMan-PCR, QIAamp DNA Blood Kit, Qiagen, Hilden, Germany)). CMV screening was performed monthly during the first six months after RTx, every second month during months 6--12, and on indication.

2.2. Tacrolimus Metabolism Rate {#sec2dot2-jcm-08-00587}
-------------------------------

Tac metabolism rates were calculated at three months after RTx by dividing the Tac blood trough concentration (C) by the corresponding daily Tac dose (D), as published before \[[@B8-jcm-08-00587],[@B16-jcm-08-00587]\].

As inpatient values are more prone to errors due to coexisting factors like diarrhea, anaemia and CYP3A4 interfering drugs as azoles, e.g., only outpatient tacrolimus concentrations were considered. Measurements with exceptional high Tac trough concentrations (\>15 ng/mL) were not considered to exclude false-high values due to Tac ingestion prior blood sampling.

For 50 randomly selected patients we additionally calculated the Tac C/D ratio at one and six months as an average C/D ratio and compared it to the three-month C/D ratio to account for further potential factors that can influence the C/D ratio and might affect single-time point measurements. As the 3-month C/D ratio strongly correlated with the average C/D ratio at month one and six, we applied the 3-month C/D ratio for the following patient categorization:

As defined previously, patients with a Tac C/D ratio \<1.05 ng/mL × 1/mg were categorized as fast metabolizers. Patients with a C/D ratio of 1.05--1.54 ng/mL × 1/mg or a C/D ratio ≥1.55 ng/mL × 1/mg were defined as intermediate metabolizers and slow metabolizers, respectively \[[@B8-jcm-08-00587]\]. For simplification, intermediate and slow metabolizers were summarized as slower metabolizers in this study.

2.3. Outcome Measures {#sec2dot3-jcm-08-00587}
---------------------

The main outcome measures were patient and overall graft survival. Patient survival was defined as time from RTx to death (from any cause) or last contact for alive patients. Overall graft survival was defined as the time from RTx to death (from any cause), graft failure, or last contact, whichever occurred first. Graft failure was defined as the reinitiation of dialysis treatment.

Further outcome parameters were serum creatinine and estimated glomerular filtration rate (eGFR) at years one to five after transplantation as well as the frequency of biopsy-proven acute rejection episodes (defined by Banff classification) and the rejection-free survival. Patients were subjected to kidney biopsy in case of a relevant rise in creatinine (≥0.3 mg/dL). Biopsies were evaluated by two pathologists.

Whole blood was analyzed for creatinine (enzymatic assay; Creatinine-Pap, Roche Diagnostics, Mannheim, Germany) and Tac (automated tacrolimus (TACR) assay; Dimension Clinical Chemistry System; Siemens Healthcare Diagnostic GmbH; Eschborn; Germany). Only 12 h Tac trough levels were used for analysis. Renal function was determined by calculating the eGFR using the CKD-EPI equation.

2.4. Statistical Analysis {#sec2dot4-jcm-08-00587}
-------------------------

Statistical analysis was performed using IBM SPSS^®^ Statistics 25 for Windows (IBM Corporation, Somers, NY, USA). Normally distributed continuous variables are shown as mean ± standard deviation (SD) and non-normally distributed continuous variables as median and 1st and 3rd quartiles (interquartile range, IQR). Absolute and relative frequencies have been given for categorical variables. Pairs of independent groups were compared using the Student's t-test for normally distributed data, Mann--Whitney U test for non-normal data, and Fisher's exact test for categorical variables. To compare paired data, we used the Wilcoxon test for continuous variables and the McNemar test for categorical variables.

Survival analyses were based on a maximum follow-up of five years after RTx. Patient survival, overall allograft survival as well as rejection-free survival were analyzed using the Kaplan-Meier method \[[@B17-jcm-08-00587]\], and the groups were compared using the log-rank test. Cox proportional hazards regression models \[[@B18-jcm-08-00587]\] were built using a stepwise variable selection procedure to assess the association between C/D ratio metabolism status and survival while simultaneously adjusting for potential confounding factors (inclusion: *p*-value of the score test ≤ 0.05, exclusion: *p*-value of the likelihood ratio test \> 0.1). Results have been presented as hazard ratios (HR) with 95% confidence interval (95% CI) and *p*-value of likelihood ratio test. The *p*-value of score test is given for non-selected variables in multivariable analyses.

Mixed models with AR (1) covariance structure were fitted to analyze the impact of biological and clinical markers on the time course of eGFR between year one and five after the transplantation based on the eGFR values observed at annual intervals during this period. Univariable analyses included each marker separately along with its interaction with time since baseline measurement (at year one after transplantation) in order to assess (i) the baseline eGFR and/or (ii) whether potential time trends of eGFR differ between the subgroups defined by the marker. Multivariable models were built using a stepwise variable selection procedure in order to assess the impact of C/D ratio metabolism status on baseline eGFR and time trends of eGFR while adjusting for potential confounding factors. Models included (i) C/D ratio metabolism status and its interaction with time since baseline measurement in a first block and (ii) potential confounding factors along with their interactions with time since baseline measurement in a second block with forwards variable selection (inclusion/exclusion criterion: *p*-value of Wald test ≤0.05/\>0.1).

No adjustment for multiple testing was made, and all analyses were regarded as explorative. *p*-values ≤ 0.05 were considered statistically noticeable.

3. Results {#sec3-jcm-08-00587}
==========

3.1. Patient Cohort {#sec3dot1-jcm-08-00587}
-------------------

The enrollment flow chart for the study population is shown in [Figure 1](#jcm-08-00587-f001){ref-type="fig"}. Between January 2007 and December 2012, 633 kidney transplants were performed at our center. After the exclusion of 50 patients aged \<18 years and 25 patients with combined transplantation, data on immunosuppressive therapy was extracted from the remaining 558 adult kidney-only transplant recipients. From these, 401 patients with an initial Tac-based immunosuppressive therapy and complete data on the 3-month C/D ratio were included. From all patients, 253 recipients (63.1%) were categorized as slow metabolizers and 148 recipients (36.9%) as fast metabolizers. The average C/D ratio of month one and six for 50 randomly selected patients did not differ from the three-month C/D ratio (*p* = 0.765, [Table S1](#app1-jcm-08-00587){ref-type="app"}) and categorization of slow and fast Tac metabolizers was similar when applying the three-month C/D ratio or the average C/D ratio of months one and six (*p* = 1.000, [Table S2](#app1-jcm-08-00587){ref-type="app"}), suggesting that three-month C/D ratio strongly correlated with the average C/D ratio during months one and six.

Baseline patient characteristics for donors and recipients and transplantation-associated parameters are shown in [Table 1](#jcm-08-00587-t001){ref-type="table"}. Tac mean trough levels and daily doses were noticeably different between the groups. The two groups were similar with respect to all other baseline characteristics that were analyzed.

3.2. Patient and Overall Allograft Survival {#sec3dot2-jcm-08-00587}
-------------------------------------------

Kaplan-Meier curves for patient and overall allograft survival by Tac metabolism status are shown in [Figure 2](#jcm-08-00587-f002){ref-type="fig"}. Five-year patient survival was noticeably reduced in fast metabolizers as compared to slow metabolizers (89.9% vs. 95.3%, log-rank *p* = 0.036, [Figure 2](#jcm-08-00587-f002){ref-type="fig"}). The Cox regression analysis revealed a noticeable association between a fast Tac metabolism and patient survival in both univariable (HR 2.209 (95% CI 1.034--4.719), *p* = 0.041) as well as multivariable analysis (HR 5.749 (95% CI 1.556--21.242), *p* = 0.004) ([Table 2](#jcm-08-00587-t002){ref-type="table"}). Overall allograft survival was affected by the Tac metabolism status as well: Fast metabolizers showed a noticeably reduced 5-year allograft survival rate as compared to slow metabolizers (83.8% vs. 90.5%, log-rank *p* = 0.044, [Figure 2](#jcm-08-00587-f002){ref-type="fig"}). HR was 1.772 (95% CI 1.006--3.121, *p* = 0.047)) for fast metabolizers in univariable Cox regression and 2.715 (95% CI 1.231--5.989, *p* = 0.012) after adjustment for potential confounders ([Table 3](#jcm-08-00587-t003){ref-type="table"}).

Causes of death are given in [Table 4](#jcm-08-00587-t004){ref-type="table"}. While fast metabolizers mostly died from cardiovascular diseases (40%), the most common cause of death in slow metabolizers were infectious diseases (41.7%). In summary, a fast Tac metabolism noticeably affects patient as well as overall allograft survival after kidney transplantation.

3.3. Renal Function {#sec3dot3-jcm-08-00587}
-------------------

Renal function was assessed yearly within the first five years after transplantation. [Figure 3](#jcm-08-00587-f003){ref-type="fig"} shows the development of the eGFR between year one and five after renal transplantation in slow and fast metabolizers. A linear mixed model was applied to estimate the time-dependent course of eGFR. Fast metabolizers showed a noticeably faster decline of the eGFR within five years after transplantation as compared to slow metabolizers in both univariable (*p* = 0.040) and multivariable analysis (*p* = 0.032) ([Table 5](#jcm-08-00587-t005){ref-type="table"}a,b).

3.4. Rejections {#sec3dot4-jcm-08-00587}
---------------

The Kaplan-Meier curve for rejection-free survival is shown in [Figure 4](#jcm-08-00587-f004){ref-type="fig"}A. The 5-year rejection-free survival was noticeably lower in fast metabolizers as compared to slow metabolizers (69.6% vs. 78.8%, log-rank *p* = 0.032, [Figure 4](#jcm-08-00587-f004){ref-type="fig"}A). The Cox regression analysis revealed a noticeable association between a fast Tac metabolism and rejection-free survival in univariable (HR 1.536 (95% CI 1.034--2.282), *p* = 0.035) as well as multivariable analysis (HR 1.622 (95% CI 1.085--2.424), *p* = 0.020) ([Table 6](#jcm-08-00587-t006){ref-type="table"}). [Table 7](#jcm-08-00587-t007){ref-type="table"} shows the frequency of patients with ≥ 1 acute biopsy-proven rejection during the 5-year follow-up. While 45/148 (30.4%) fast metabolizers experienced at least one acute rejection, only 54/253 (21.3%) slow metabolizers were affected. Of note, the subtype analysis of the first rejection episode within the first five years after transplantation revealed an increased frequency of humoral and mixed rejections in fast metabolizers (*n* = 10, 6.8% vs. *n* = 9, 3.6% and *n* = 10, 6.8% vs. *n* = 6, 2.4%, respectively) ([Table 7](#jcm-08-00587-t007){ref-type="table"}, [Figure 4](#jcm-08-00587-f004){ref-type="fig"}B), whereas slow metabolizers were mainly affected by borderline rejections.

4. Discussion {#sec4-jcm-08-00587}
=============

Herein, we first described a significant influence of the Tac metabolism type on mortality after renal transplantation in a study population with a long-term observation period. A higher five-year mortality in fast metabolizers was accompanied by a higher rejection rate and inferior kidney function. Our study highlights the importance of a risk stratification strategy of RTx patients including information on individuals' Tac metabolism rate which turned out to be an independent risk factor for a lower patient survival after renal transplantation. The C/D ratio is a simple tool that can be easily applied for this purpose.

Based on our previous findings revealing an impact of fast Tac metabolism (C/D ratio \<1.05 ng/mL×1/mg) on inferior renal function in a two-and three-year follow-up after RTx or LTx \[[@B8-jcm-08-00587],[@B16-jcm-08-00587]\] we herein could demonstrate that this effect persists in the long term and that fast Tac metabolism also impacts on the time-dependent course of renal function in both univariable and multivariable analysis. Moreover, we identified fast Tac metabolism as an independent risk factor for a decreased graft survival.

In congruence, Kuypers et al. observed that patients with high early Tac dose requirements (namely, fast metabolism) had a significantly reduced kidney function at three-months post-RTx \[[@B9-jcm-08-00587]\]. This was attributed to an increased rate of calcineurin inhibitor (CNI)-related toxicity, which is in line with the observations of our previous study \[[@B8-jcm-08-00587]\]. High-dose requirement in Kuyper's study was associated with CYP3A5\*1 genotype carriage in only 1/3 of cases, suggesting further factors impacting a patient's Tac metabolism rate \[[@B2-jcm-08-00587]\]. Notably, the area under the curve and the Tac trough level were not different between patients with and without CNI toxicity. The connection between different dose requirements and comparable trough levels in groups--although not calculated--hints at different C/D ratio categories of patients in both groups. Further, Genvigir et al. showed in a Brazilian cohort of CYP3A genotyped RTx patients that expression of CYP3A4/5 alleles leading to fast Tac metabolism (they also calculated the C/D ratio but did not calculate a cut-off) was associated with a lower eGFR at 3-months after RTx \[[@B15-jcm-08-00587]\]. Again, no association was found between Tac exposure and the genetic score. By applying a multiple linear regression analysis, they showed that genetic variants and age impacted the C/D ratio. This is consistent with the literature -- metabolism rate usually decreases with age -- and with our findings that show tendencies of slow metabolizers being older age \[[@B8-jcm-08-00587]\] ([Table 1](#jcm-08-00587-t001){ref-type="table"}). Given the limitations of genetic testing-based strategies, we refrained from genotyping our patients but rather searched for a simple and cost-effective tool, as the C/D ratio, that can assist physicians in the daily routine to individualize their patients' immunosuppressive therapy and stratify individuals with high risk for Tac-related side effects independent from complex genotyping-based methods.

In both aforementioned studies, rejection rates were calculated but not related to the C/D ratio or the dose requirements. However, as Kuypers et al. observed significantly higher rates of graft failure (32.3% vs. 13.7%) and lower rates of patients discontinuing steroids (5.8% vs. 23.7%) in patients requiring higher Tac doses, one can assume a higher rejection rate in these patients. We herein firstly describe a significant effect of the C/D ratio on acute rejections in a long-term follow up. In our study, rejection-free survival was increased in slow metabolizers, with higher frequencies of humoral and mixed rejections in fast than in slow metabolizers. In multivariable regression analysis, the BMI and the number of prior transplantations were associated with rejection as well. Recently, Barraclough et al. stated that the outcome of RTx patients depends on the immunosuppression within the first week after transplantation, although a relation between the AUC or Tac trough level and rejection was not detected \[[@B19-jcm-08-00587]\]. Of note, as mentioned before, Tac AUC and trough levels are usually similar in slow and fast metabolizers and the C/D ratio was not calculated in their study. In a meta-analysis including data from the FDCC, Symphony, and OptiCept studies, Boumar et al. reported that the Tac trough concentration was not different between patients with and without acute rejection within the first 6 months after RTx \[[@B20-jcm-08-00587]\]. Again, information regarding the Tac doses or the C/D ratio was not provided. In this regard, Egeland et al. observed that a high Tac clearance (or a fast metabolism) was associated with an increased risk of developing an acute rejection within the first few days after RTx \[[@B10-jcm-08-00587]\]. Patients with a high Tac clearance might not reach the trough levels in time and suffer under-immunosuppression (at least at some time of the day).

Mortality in fast metabolizers over the five-year observation period was consistently higher than in slow metabolizers, despite a tendency towards an older age in slow metabolizers. Overall, graft failure was low in both groups but aligned with the data from the literature \[[@B21-jcm-08-00587],[@B22-jcm-08-00587]\]. In a recently published large registry analysis from England, the main reasons of death within the first year after RTX were stated as infection (21.6%), cardiovascular events (18.3%), and malignancy (7.4%) \[[@B21-jcm-08-00587]\]. The main reasons of death in our cohort were cardiovascular diseases in fast metabolizers and infections in slow metabolizers, respectively, but did not differ between groups. Unfortunately, the reason of death remained unclear in 33.3% of cases in fast and 8.3% cases in slow metabolizers. As previously observed, fast metabolizers are more prone to developing BK virus infection than slow metabolizers. Thus, one can speculate that over-immunosuppression is an issue in these patients \[[@B12-jcm-08-00587]\]. However, other infections, e.g., urinary tract infections, have not been shown to be related to the C/D ratio \[[@B23-jcm-08-00587]\], and deaths due to infection were not different between groups in our cohort. This aligns with the fact that Tac mainly suppresses T-cell activity while the host's defense to bacterial infections, which are more fatal in RTx patients than viral infections, is mainly based on innate immune cells \[[@B24-jcm-08-00587]\]. Interestingly, 20% of death certificates in the English registry study stated "renal" as the cause of death within the first year after RTx \[[@B21-jcm-08-00587]\]. Lastly, we were unable to identify a difference in reasons of death between groups. One reason for this could be the low mortality rate. However, factors that have been previously associated with increased risk of death, such as age at transplantation, diabetes, time on dialysis, or postmortal donation were not different between groups but rather distributed in favor of the fast metabolizer group ([Table 1](#jcm-08-00587-t001){ref-type="table"}). Patient demographics associated with kidney function after RTx, such as living donation, number of transplants, cold ischemia time, hypertension, diabetes, donor age, and gender, did not differ between groups. This implies that the differences in renal function are likely to be related to Tac metabolism and rejection. Consequently, an inferior renal function is associated with higher mortality as cardiovascular events, infections as well as malignancies are related to kidney function \[[@B25-jcm-08-00587]\].

We recognize that a study of this nature has limitations because of its retrospective design and potential errors inherent to maintaining a single-center database. Moreover, due to the relatively small patient size, inaccuracies in the data collection might affect the results; though data acquisition was performed thoroughly to avoid inconsistency or entry errors. The analyses are based on the assumption that coding errors and missing data are stochastic. Although we attempted to include as many relevant confounding parameters as possible there might still be residual factors that were not accounted for like the non-adherence of patients for example, which is difficult to measure. Prospective studies are needed to confirm our findings. We conclude from our data that the calculation of the C/D ratio, as a simple, cost-effective tool, can assist physicians in their daily clinical routine to identify Tac-treated patients at risk of developing an inferior graft function, acute rejections, or even higher mortality. This information should be used to individualize and optimize immunosuppressive therapy.

The following are available online at <https://www.mdpi.com/2077-0383/8/5/587/s1>, Table S1: The average C/D ratio of month one and six for 50 randomly selected patients did not differ from the 3-month C/D ratio, suggesting that 3-month C/D ratio strongly correlated with the average C/D ratio during month one and six. P-value of Mann-Whitney U test is given, Table S2: Categorization of slow and fast Tac metabolizers was similar when applying the 3-month C/D ratio or the average C/D ratio of month one and six (*p* = 1.000, Fisher's exact test).

###### 

Click here for additional data file.
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![Enrollment flow chart for the study population. RTx = Renal transplantation; N/A: not available.](jcm-08-00587-g001){#jcm-08-00587-f001}

![(**A**) Kaplan-Meier curves for patient survival and (**B**) overall graft survival. Survival rates of slow (red lines) and fast metabolizers (blue lines) were analyzed by the Kaplan--Meier method and compared using the log-rank test. Fast metabolizers showed a noticeably reduced patient and overall graft survival.](jcm-08-00587-g002){#jcm-08-00587-f002}

![Time course of the eGFR within five years after renal transplantation. Fast metabolizers show a faster decline in the eGFR as compared to slow metabolizers over the first five years.](jcm-08-00587-g003){#jcm-08-00587-f003}

![(**A**) Kaplan-Meier curves for rejection-free survival of slow (red lines) and fast metabolizers (blue lines), analyzed by the Kaplan--Meier method and compared using the log-rank test. Fast metabolizers showed a noticeably reduced rejection-free survival. (**B**) Subtype analysis of the first rejection episode within the first five years after transplantation. Fast metabolizers experienced increased frequencies of humoral and mixed acute rejection, whereas slow metabolizers were mainly affected by borderline rejections.](jcm-08-00587-g004){#jcm-08-00587-f004}

jcm-08-00587-t001_Table 1

###### 

Baseline patient characteristics.

                                                 Slow Metabolizers (*n* = 253)   Fast Metabolizers (*n* = 148)   *p*-Value
  ---------------------------------------------- ------------------------------- ------------------------------- -------------
  Tac mean trough level at 3 months (ng/mL)      8.6 ± 2.8                       7.1 ± 2.7                       \<0.001 ^a^
  Tac daily dose at 3 months (mg/day)            4.9 ± 2.3                       10.3 ± 4.3                      \<0.001 ^a^
  Age (years, mean ± SD)                         53.0 ± 13.4                     50.2 ± 13.8                     0.051 ^a^
  Male sex, *n* (%)                              156 (61.7)                      80 (54.1)                       0.142 ^c^
  BMI (kg/m^2^, mean ± SD)                       25.2 ± 4.0                      25.2 ± 4.1                      0.944 ^a^
  Pre-existing recipient hypertension, *n* (%)   239 (94.5)                      139 (94.6)                      1.000 ^c^
  Pre-existing recipient diabetes, *n* (%)       33 (13.0)                       16 (10.9)                       0.636 ^c^
  Diagnosis of ESRD, *n* (%)                                                                                     0.411 ^c^
  Hypertension                                   20 (7.9)                        11 (7.4)                        
  Diabetes                                       11 (4.3)                        1 (0.7)                         
  Polycystic kidney disease                      36 (14.2)                       26 (17.6)                       
  Obstructive Nephropathy                        20 (7.9)                        14 (9.5)                        
  Glomerulonephritis                             103 (40.7)                      53 (35.8)                       
  FSGS                                           6 (2.4)                         5 (3.4)                         
  Interstitial nephritis                         4 (1.6)                         2 (1.4)                         
  Vasculitis                                     5 (2.0)                         2 (1.4)                         
  Other                                          45 (17.8)                       34 (23.0)                       
  Time on dialysis (months, median (IQR))        60.5 (25.5, 90.3)               52.5 (24.9, 87.1)               0.323 ^b^
  ≥ 1 prior kidney transplant, *n* (%)           39 (15.4)                       19 (12.8)                       0.557 ^c^
  Living donor transplantation                   58 (22.9)                       44 (29.7)                       0.4 ^c^
  Number HLA mismatch, *n* (%)                                                                                   1.000 ^c^
  0--3                                           169 (67.1)                      98 (66.7)                       
  4--6                                           83 (32.9)                       49 (33.3)                       
  Current PRA, *n* (%)                                                                                           1.000 ^c^
  0--20%                                         248 (98.0)                      145 (98.0)                      
  \> 20%                                         5 (2.0)                         3 (2.0)                         
  Induction, *n* (%)                                                                                             0.163 ^c^
  Basiliximab                                    233 (92.1)                      130 (87.8)                      
  Thymoglobulin                                  20 (7.9)                        18 (12.2)                       
  Cold ischaemia time (hours, mean ± SD)         8.7 ± 4.9                       8.2 ± 5.4                       0.419 ^a^
  Warm ischaemia time (min, mean ± SD)           31.8 ± 6.9                      32.2 ± 8.0                      0.684 ^a^
  Donor age (years, mean ± SD)                   53.4 ± 16.6                     54.7 (13.7)                     0.394 ^a^
  Donor male sex, *n* (%)                        121 (47.8)                      63 (42.6)                       0.350 ^c^

Demographic characteristics of the study population by the Tac metabolization status. Results are presented as mean ± standard deviation (SD) or median and first and third quartile (IQR), respectively, or as absolute and relative frequencies. BMI = body mass index; ESRD = end-stage renal disease; FSGS = focal segmental glomerulosclerosis; HLA = human leukocyte antigen; PRA = panel reactive antibodies. ^a^ Student's *t*-test, ^b^ Mann-Whitney U test, ^c^ Fisher's exact test.

jcm-08-00587-t002_Table 2

###### 

Univariable and multivariable analyses of patient survival using Cox regression.

  --------------------------------------------------------------------------------------------------------------
  Parameters                             Univariable             Multivariable                           
  -------------------------------------- ----------------------- --------------- ----------------------- -------
  Fast metabolizers vs. slow\            2.209 (1.034--4.719)    0.041           5.749 (1.556--21.242)   0.004
  metabolizers (ref.)                                                                                    

  Age (years)                            1.057 (1.023--1.093)    0.001           \-                      0.081

  Recipient sex\                         1.631 (0.714--3.727)    0.246           \-                      0.262
  Male vs. female (ref.)                                                                                 

  Recipient BMI (kg/m^2^)                0.942 (0.852--1.042)    0.248           \-                      0.213

  Pre-existing recipient hypertension\   1.512 (0.205--11.142)   0.685           \-                      0.635
  yes vs. no (ref.)                                                                                      

  Pre-existing recipient diabetes\       2.206 (0.890--5.468)    0.087           \-                      0.691
  yes vs. no (ref.)                                                                                      

  Cause of ESRD                          \-                      0.852           \-                      0.738

  Time on dialysis (months)              1.002 (0.993--1.011)    0.714           \-                      0.553

  Prior kidney transplantation\          1.379 (0.522--3.641)    0.517           \-                      0.707
  ≥1 vs. 0 (ref.)                                                                                        

  Donor type\                            2.832 (0.853--9.405)    0.089           \-                      0.936
  Postmortal vs. living donor (ref.)                                                                     

  Number HLA mismatch\                   2.335 (1.097--4.968)    0.028           \-                      0.053
  4--6 vs. 0--3                                                                                          

  Current PRA\                           1.951 (0.265--14.387)   0.512           \-                      0.709
  \>20% vs. 0--20%                                                                                       

  Cold ischemia time (hours)             1.042 (0.972--1.118)    0.245           \-                      0.668

  Donor age (years)                      1.043 (1.014--1.074)    0.004           \-                      0.540

  Donor sex\                             0.928 (0.434--1.982)    0.847           \-                      0.266
  Male vs. female (ref.)                                                                                 

  NODAT\                                 2.983 (1.396--6.373)    0.005           5.150 (1.550--17.110)   0.005
  yes vs. no (ref.)                                                                                      

  CMV DNAaemia\                          0.832 (0.352--1.968)    0.676           \-                      0.629
  yes vs. no (ref.)                                                                                      

  Acute rejection within 1 year\         1.610 (0.680--3.807)    0.279           \-                      0.947
  yes vs. no (ref.)                                                                                      

  eGFR at month 3 (mL/min/1.73m^2^)      0.979 (0.960--0.998)    0.028           \-                      0.999

  eGFR at month 12 (mL/min/1.73m^2^)     0.968 (0.937--1.000)    0.047           \-                      0.166
  --------------------------------------------------------------------------------------------------------------

Results are presented as hazard ratios (HR) with their 95% confidence interval (CI) and *p*-value of likelihood ratio test. For non-selected variables in multivariable analyses, *p*-value of score test is given. HR = hazard ratio; CI = confidence interval.
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###### 

Univariable and multivariable analyses of overall graft survival using Cox regression.

  -----------------------------------------------------------------------------------------------------------
  Parameters                             Univariable             *p*-Value                          
  -------------------------------------- ----------------------- ----------- ---------------------- ---------
  Fast metabolizers vs. slow\            1.772 (1.006--3.121)    0.047       2.715 (1.231--5.989)   0.012
  metabolizers (ref.)                                                                               

  Age (years)                            1.056 (1.030--1.082)    \<0.001     \-                     0.673

  Recipient sex\                         0.957 (0.539--1.698)    0.880       \-                     0.354
  Male vs. female (ref.)                                                                            

  Recipient BMI (kg/m^2^)                1.018 (0.949--1.092)    0.619       \-                     0.715

  Pre-existing recipient hypertension\   2.797 (0.386--20.272)   0.309       \-                     0.401
  yes vs. no (ref.)                                                                                 

  Pre-existing recipient diabetes\       2.044 (1.018--4.102)    0.044       \-                     0.827
  yes vs. no (ref.)                                                                                 

  Cause of ESRD                          \-                      0.717       \-                     0.942

  Time on dialysis (months)              0.999 (0.992--1.007)    0.833       \-                     0.376

  Prior kidney transplantation\          0.702 (0.278--1.772)    0.454       \-                     0.331
  ≥1 vs. 0 (ref.)                                                                                   

  Donor type\                            3.121 (1.236--7.879)    0.016       \-                     0.774
  Postmortem vs. living donor (ref.)                                                                

  Number HLA mismatch\                   1.814 (1.028--3.201)    0.040       \-                     0.504
  4--6 vs. 0--3                                                                                     

  Current PRA\                           1.073 (0.148--7.780)    0.944       \-                     0.709
  \>20% vs. 0--20%                                                                                  

  Cold ischemia time (hours)             1.060 (1.006--1.116)    0.028       \-                     0.427

  Donor age (years)                      1.052 (1.029--1.075)    \<0.001     \-                     0.485

  Donor sex\                             0.567 (0.311--1.034)    0.064       \-                     0.140
  Male vs. female (ref.)                                                                            

  NODAT\                                 3.163 (1.787--5.596)    \<0.001     3.203 (1.451--7.072)   0.003
  yes vs. no (ref.)                                                                                 

  CMV DNAaemia\                          1.331 (0.737--2.404)    0.344       \-                     0.443
  yes vs. no (ref.)                                                                                 

  Acute rejection within one year\       1.909 (1.024--3.558)    0.042       \-                     0.943
  yes vs. no (ref.)                                                                                 

  eGFR at month 3 (mL/min/1.73m^2^)      0.958 (0.941--0.976)    \<0.001     \-                     0.851

  eGFR at month 12 (mL/min/1.73m^2^)     0.941 (0.916--0.967)    \<0.001     0.943 (0.915--0.971)   \<0.001
  -----------------------------------------------------------------------------------------------------------

Results are presented as hazard ratios (HR) with their 95% confidence interval (CI) and *p*-value of likelihood ratio test. For non-selected variables in multivariable analyses, *p*-value of score test is given. HR = hazard ratio; CI = confidence interval.
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###### 

Causes of death for slow and fast metabolizers.

                   Slow Metabolizers (*n* = 12)   Fast Metabolizers (*n* = 15)
  ---------------- ------------------------------ ------------------------------
  Cardiovascular   4 (33.3)                       6 (40)
  Infection        5 (41.7)                       4 (26.7)
  Tumor disease    2 (16.7)                       \-
  Unknown          1 (8.3%)                       5 (33.3)
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###### 

\(a\) Univariable Analysis: eGFR at month 12 and linear time-trends of eGFR (between months 12 and 60) by subgroup/marker. (b) Multivariable Analysis: eGFR at month 12 and linear time-trends of eGFR (between month 12 and 60) by subgroup/marker.

  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ------------------ ---------------
  (**a**)                                                                                                                                                                                                                                                                                                                                         

                                    **Variable**                                                                                                                                                                                                                                                                **B**          **95% CI**         ***p***

  Metabolizer type                                                                                                                                                                                                                                                                                                                                

                                    Fast vs. slow (at month 12)                                                                                                                                                                                                                                                 −3.54          −8.57 to 1.49      0.167

                                    Fast vs slow (time-trends)                                                                                                                                                                                                                                                  −1.07          −2.10 to −0.05     0.040

  R_Sex                                                                                                                                                                                                                                                                                                                                           

                                    Male vs. female (at month 12)                                                                                                                                                                                                                                               −16.21         −1.26 to −11.61    \<0.001

                                    Male vs. female (time-trends)                                                                                                                                                                                                                                               0.49           −0.49 to 1.47      0.325

  PreHypertension                                                                                                                                                                                                                                                                                                                                 

                                    No vs. yes (at month 12)                                                                                                                                                                                                                                                    0.78           −9.63 to 11.19     0.883

                                    No vs. yes (time-trends)                                                                                                                                                                                                                                                    1.26           −0.79 to 0.20      0.240

  PreDiabetes                                                                                                                                                                                                                                                                                                                                     

                                    No vs. yes (at month 12)                                                                                                                                                                                                                                                    4.52           −3.04 to 12.08     0.241

                                    No vs. yes (time-trends)                                                                                                                                                                                                                                                    0.91           −0.68 to 2.51      0.262

  Cause of ESRD                                                                                                                                                                                                                                                                                                                                   

                                    Cause of ESRD (at month 12)                                                                                                                                                                                                                                                 \-             \-                 0.010 \*

                                    Diabetes vs. Hypertension (at month 12)                                                                                                                                                                                                                                     3.72           −15.38 to 22.82    0.703

                                    Polycystic kidney disease vs. Hypertension (at month 12)                                                                                                                                                                                                                    8.30           −1.90 to 18.50     0.111

                                    Obstructive Nephropahty vs. Hypertension (at month 12)                                                                                                                                                                                                                      16.20          4.91 to 27.48      0.005

                                    Glomerulonephritis vs. Hypertension (at month 12)                                                                                                                                                                                                                           5.82           −3.12 to 14.76     0.202

                                    FSGS vs. Hypertension (at month 12)                                                                                                                                                                                                                                         7.14           −10.58 to 24.85    0.429

                                    Interstitial nephritis vs. Hypertension (at month 12)                                                                                                                                                                                                                       11.40          −8.85 to 31.65     0.269

                                    Vasculitis vs. Hypertension (at month 12)                                                                                                                                                                                                                                   2.51           −16.28 to 21.32    0.792

                                    Other vs. Hypertension (at month 12)                                                                                                                                                                                                                                        16.81          7.14 to 26.48      0.001

                                    Cause of ESRD (time-trends)                                                                                                                                                                                                                                                 \-             \-                 0.998 \*

  PriorTx                                                                                                                                                                                                                                                                                                                                         

                                    No vs. yes (at month 12)                                                                                                                                                                                                                                                    −8.67          −15.48 to −1.86    0.013

                                    No vs. yes (time-trends)                                                                                                                                                                                                                                                    0.25           −1.13 to 1.63      0.719

  DonorType                                                                                                                                                                                                                                                                                                                                       

                                    Postmortal vs. Living (at month 12)                                                                                                                                                                                                                                         −11.15         −16.40 to −5.90    \<0.001

                                    Postmortal vs. Living ( time-trends)                                                                                                                                                                                                                                        0.47           −0.60 to 1.55      0.387

  HLA Mismatch                                                                                                                                                                                                                                                                                                                                    

                                    0--3 vs. 4--6 (at month 12)                                                                                                                                                                                                                                                 5.45           0.37 to 10.53      0.035

                                    0--3 vs. 4--6 (time-trends)                                                                                                                                                                                                                                                 −0.21          −1.25 to 0.83      0.696

  CurrentPRA                                                                                                                                                                                                                                                                                                                                      

                                    0--20 vs. \>20 (at month 12)                                                                                                                                                                                                                                                −14.81         −32.19 to 2.57     0.095

                                    0--20 vs. \>20 (time-trends)                                                                                                                                                                                                                                                −0.80          −4.15 to 2.54      0.638

  D_Sex                                                                                                                                                                                                                                                                                                                                           

                                    Male vs. female (at month 12)                                                                                                                                                                                                                                               4.31           −0.47 to 9.09      0.077

                                    Male vs. female (time-trends)                                                                                                                                                                                                                                               −0.36          −1.32 to 0.62      0.470

  NODAT                                                                                                                                                                                                                                                                                                                                           

                                    No vs. yes (at month 12)                                                                                                                                                                                                                                                    6.50           1.31 to 11.69      0.014

                                    No vs. yes (time-trends)                                                                                                                                                                                                                                                    0.52           −0.56 to 1.60      0.342

  CMV DNAaemia                                                                                                                                                                                                                                                                                                                                    

                                    No vs. yes (at month 12)                                                                                                                                                                                                                                                    4.46           −0.74 to 9.66      0.093

                                    No vs. yes (time-trends)                                                                                                                                                                                                                                                    −0.26          −1.32 to 0.80      0.629

  Acute rejection 1 year post RTx                                                                                                                                                                                                                                                                                                                 

                                    No vs. yes (at month 12)                                                                                                                                                                                                                                                    16.23          10.34 to 22.13     \<0.001

                                    No vs. yes (time-trends)                                                                                                                                                                                                                                                    0.09           −1.18 to 1.35      0.893

  R-Age (years)                                                                                                                                                                                                                                                                                                                                   

                                    R-Age (at month 12)                                                                                                                                                                                                                                                         −0.47          −0.63 to −0.32     \<0.001

                                    R-Age (time-trends)                                                                                                                                                                                                                                                         −0.004         −0.013 to 0.005    0.415

  R-BMI                                                                                                                                                                                                                                                                                                                                           

                                    R-BMI (at month 12)                                                                                                                                                                                                                                                         −1.12          −1.67 to −0.57     \<0.001

                                    R-BMI (time-trends)                                                                                                                                                                                                                                                         −0.008         −0.027 to 0.011    0.405

  Time on Dialysis (month)                                                                                                                                                                                                                                                                                                                        

                                    Time on Dialysis (at month 12)                                                                                                                                                                                                                                              −0.05          −0.11 to 0.01      0.112

                                    Time on Dialysis (time-trends)                                                                                                                                                                                                                                              −0.012         −0.008 to 0.006    0.743

  CIT (hours)                                                                                                                                                                                                                                                                                                                                     

                                    CIT (at month 12)                                                                                                                                                                                                                                                           −0.43          −0.86 to 0.004     0.052

                                    CIT (time-trends)                                                                                                                                                                                                                                                           −0.014         −0.064 to 0.034    0.565

  D_Age (years)                                                                                                                                                                                                                                                                                                                                   

                                    D-Age (at month 12)                                                                                                                                                                                                                                                         −0.65          −0.78 to −0.52     \<0.001

                                    D-Age (time-trends)                                                                                                                                                                                                                                                         −0.006         −0.015 to 0.002    0.152

  (**b**)                                                                                                                                                                                                                                                                                                                                         

                                    **Variable**                                                                                                                                                                                                                                                                **Estimate**   **95% CI**         ***p***

  At month 12                                                                                                                                                                                                                                                                                                                                     

                                    Metabolizer type: fast vs. slow                                                                                                                                                                                                                                             −2.48          −6.47 to 1.51      0.222

                                    D_Age (years)                                                                                                                                                                                                                                                               −0.60          −0.71 to −0.48     \<0.001

                                    R_Sex: male vs. female                                                                                                                                                                                                                                                      −12.27         −15.75 to −8.79    \<0.001

                                    Donor type: postmortem vs. living                                                                                                                                                                                                                                           −10.03         −13.94 to −6.12    \<0.001

                                    R_BMI (kg/m^2^)                                                                                                                                                                                                                                                             −0.58          −1.03 to −0.14     0.010

                                    PreHypertension: no vs. yes                                                                                                                                                                                                                                                                                   N/S: 0.051

                                    PreDiabetes: no vs. yes                                                                                                                                                                                                                                                                                       N/S: 0.914

                                    Cause of ESRD Diabetes vs. HypertensionPolycystic kidney disease vs. HypertensionObstructive Nephropathy vs. HypertensionGlomerulonephritis vs. HypertensionFSGS vs. HypertensionInterstitial nephritis vs. HypertensionVasculitis vs. HypertensionOther vs. Hypertension   10.79\         −2.08 to 23.65\    0.010 \*\
                                                                                                                                                                                                                                                                                                                4.72\          −2.57 to 12.02\    0.100\
                                                                                                                                                                                                                                                                                                                11.34\         3.11 to 19.56\     0.204\
                                                                                                                                                                                                                                                                                                                2.83\          −3.53 to 9.19\     0.007\
                                                                                                                                                                                                                                                                                                                5.16\          −6.98 to 17.31\    0.382\
                                                                                                                                                                                                                                                                                                                2.23\          −14.60 to 19.06\   0.404\
                                                                                                                                                                                                                                                                                                                −0.31\         −13.54 to 12.93\   0.794\
                                                                                                                                                                                                                                                                                                                11.26          4.30 to 18.22      0.964\
                                                                                                                                                                                                                                                                                                                                                  0.002

                                    PriorTx: no vs yes                                                                                                                                                                                                                                                                                            N/S: 0.225

                                    HLAMismatch: 0--3 vs. 4--6                                                                                                                                                                                                                                                                                    N/S: 0.713

                                    CurrentPRA: 0--20 vs. \>20                                                                                                                                                                                                                                                                                    N/S: 0.272

                                    D_Sex: male vs. female                                                                                                                                                                                                                                                                                        N/S: 0.107

                                    NODAT: no vs. yes                                                                                                                                                                                                                                                                                             N/S: 0.995

                                    CMV DNAaemia: no vs. yes                                                                                                                                                                                                                                                                                      N/S: 0.417

                                    Acute rejection 1 year post RTx: no vs. yes                                                                                                                                                                                                                                 14.00          9.64 to 18.36      \<0.001

                                    R_Age (years)                                                                                                                                                                                                                                                                                                 N/S: 0.495

                                    Time Dialysis (months)                                                                                                                                                                                                                                                                                        N/S: 0.112

                                    CIT (hours)                                                                                                                                                                                                                                                                                                   N/S: 0.771

  Time trends                                                                                                                                                                                                                                                                                                                                     

                                    Metabolizer type: fast vs. slow                                                                                                                                                                                                                                             −1.07          −2.05 to −0.09     0.032

                                    D_Age (years)                                                                                                                                                                                                                                                                                                 N/S: 0.121

                                    R_Sex: male vs. female                                                                                                                                                                                                                                                                                        N/S: 0.240

                                    Donor Type: postmortem vs. living                                                                                                                                                                                                                                                                             N/S: 0.666

                                    R_BMI (kg/m^2^)                                                                                                                                                                                                                                                                                               N/S: 0.810

                                    PreHypertension: no vs. yes                                                                                                                                                                                                                                                                                   N/S: 0.366

                                    PreDiabetes: no vs. yes                                                                                                                                                                                                                                                                                       N/S: 0.354

                                    Cause of ESRD                                                                                                                                                                                                                                                                                                 N/S: 0.997 \*

                                    PriorTx: no vs. yes                                                                                                                                                                                                                                                                                           N/S: 0.635

                                    HLAMismatch: 0--3 vs. 4--6                                                                                                                                                                                                                                                                                    N/S: 0.299

                                    CurrentPRA: 0--20 vs. \>20                                                                                                                                                                                                                                                                                    N/S: 0.708

                                    D_Sex: male vs. female                                                                                                                                                                                                                                                                                        N/S: 0.293

                                    NODAT: no vs. yes                                                                                                                                                                                                                                                                                             N/S: 0.368

                                    CMV DNAaemia: no vs. yes                                                                                                                                                                                                                                                                                      N/S: 0.519

                                    Acute rejection1 year post RTx: no vs. yes                                                                                                                                                                                                                                                                    N/S: 0.913

                                    R_Age (years)                                                                                                                                                                                                                                                                                                 N/S: 0.332

                                    Time Dialysis (months)                                                                                                                                                                                                                                                                                        N/S: 0.840

                                    CIT (hours)                                                                                                                                                                                                                                                                                                   N/S: 0.400
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------- ------------------ ---------------

\* *p*-value of F-test (global test).
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###### 

Cox regression model for rejection-free survival. Univariable and multivariable analyses of rejection-free survival using Cox regression. Results are presented as hazard ratios (HR) with their 95% confidence interval (CI) and *p*-value of likelihood ratio test. For non-selected variables in multivariable analyses, *p*-value of score test is given.

  ------------------------------------------------------------------------------------------------------------
  Parameters                             Univariable            Multivariable                          
  -------------------------------------- ---------------------- --------------- ---------------------- -------
  Fast metabolizers vs. slow\            1.536 (1.034--2.282)   0.035           1.622 (1.085--2.424)   0.020
  metabolizers (ref.)                                                                                  

  Age (years)                            0.996 (0.981--1.010)   0.547           \-                     0.615

  Recipient sex\                         1.432 (0.943--2.176)   0.092           \-                     0.122
  Male vs. female (ref.)                                                                               

  Recipient BMI (kg/m^2^)                1.057 (1.007--1.110)   0.026           1.073 (1.021--1.128)   0.006

  Pre-existing recipient hypertension\   1.379 (0.507--3.751)   0.529           \-                     0.695
  yes vs. no (ref.)                                                                                    

  Pre-existing recipient diabetes\       1.032 (0.564--1.887)   0.919           \-                     0.716
  yes vs. no (ref.)                                                                                    

  Cause of ESRD                          \-                     0.999           \-                     0.998

  Time on dialysis (months)              1.000 (0.996--1.005)   0.862           \-                     0.746

  Prior kidney transplantation\          1.632 (0.999--2.665)   0.051           1.850 (1.109--3.087)   0.027
  ≥1 vs. 0 (ref.)                                                                                      

  Donor type\                            0.765 (0.498--1.174)   0.220           \-                     0.249
  Postmortem vs. living donor (ref.)                                                                   

  Number HLA mismatch\                   1.043 (0.683--1.593)   0.845           \-                     0.905
  4--6 vs. 0--3                                                                                        

  Current PRA\                           1.033 (0.255--4.189)   0.964           \-                     0.830
  \>20% vs. 0--20%                                                                                     

  Cold ischaemia time (hours)            0.986 (0.948--1.026)   0.489           \-                     0.620

  Donor age (years)                      1.002 (0.989--1.014)   0.788           \-                     0.846

  Donor sex\                             0.936 (0.629--1.391)   0.742           \-                     0.632
  Male vs. female (ref.)                                                                               
  ------------------------------------------------------------------------------------------------------------

HR = hazard ratio; CI = confidence interval.
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###### 

Frequencies of acute rejections and subtype analysis of the first rejection after RTx within five years after transplantation. Fast metabolizers showed increased frequencies of acute biopsy-proven rejections as compared to slow metabolizers. The *p*-value from Fisher's exact test is given.

                            Slow Metabolizers (*n* = 253)   Fast Metabolizers (*n* = 148)   *p*-Value
  ------------------------- ------------------------------- ------------------------------- -----------
  Type of acute rejection                                                                   0.084
  No rejection              199 (78.7)                      103 (69.6)                      
  Humoral                   9 (3.6)                         10 (6.8)                        
  Mixed                     6 (2.4)                         10 (6.8)                        
  Cellular                  15 (5.9)                        12 (8.1)                        
  Borderline                24 (9.5)                        13 (8.8)                        

[^1]: These authors contributed equally to this work.
